scholarly journals A Validation Method for EPID In Vivo Dosimetry Algorithms

2021 ◽  
Vol 11 (22) ◽  
pp. 10715
Author(s):  
Marco Esposito ◽  
Livia Marrazzo ◽  
Eleonora Vanzi ◽  
Serenella Russo ◽  
Stefania Pallotta ◽  
...  
Keyword(s):  
Evaluation Method ◽  
Projection Algorithm ◽  
In Vivo Dosimetry ◽  
The Novel ◽  
Back Projection ◽  
Dose Distributions ◽  
Radiochromic Films ◽  
Dc Algorithm ◽  
The Brain

The aim of this study was to develop and apply an evaluation method for assessing the accuracy of a novel 3D EPID back-projection algorithm for in vivo dosimetry. The novel algorithm of Dosimetry Check (DC) 5.8 was evaluated. A slab phantom homogeneously filled, or with air and bone inserts, was used for fluence reconstruction of different squared fields. VMAT plans in different anatomical sites were delivered on an anthropomorphic phantom. Dose distributions were measured with radiochromic films. The 2D Gamma Agreement Index (GAI) between the DC and the film dose distributions (3%, 3 mm) was computed for assessing the accuracy of the algorithm. GAIs between films and TPS and between DC and TPS were also computed. The fluence reconstruction accuracy was within 2% for all squared fields in the three slabs’ configurations. The GAI between the DC and the film was 92.7% in the prostate, 92.9% in the lung, 96.6% in the head and the neck, and 94.6% in the brain. An evaluation method for assessing the accuracy of a novel EPID algorithm was developed. The DC algorithm was shown to be able to accurately reconstruct doses in all anatomic sites, including the lung. The methodology described in the present study can be applied to any EPID back-projection in vivo algorithm.

SU-F-SPS-06: Implementation of a Back-Projection Algorithm for 2D in Vivo Dosimetry with An EPID System

2016 ◽  
Vol 43 (6Part4) ◽  
pp. 3351-3351
Author(s):  
B Hernandez Reyes ◽  
E Rodriguez Perez ◽  
M Sosa Aquino
Keyword(s):  
Projection Algorithm ◽  
In Vivo Dosimetry ◽  
Back Projection

SU-E-T-485: In Vivo Dosimetry with EBT3 Radiochromic Films for TBI Treatments

2015 ◽  
Vol 42 (6Part19) ◽  
pp. 3446-3446 ◽  
Author(s):  
S Lozares ◽  
M Gracia ◽  
J Olasolo ◽  
N Gallardo ◽  
N Fuentemilla ◽  
...  
Keyword(s):  
In Vivo Dosimetry ◽  
Radiochromic Films

PO-1350: In vivo dosimetry with XR-RV3 radiochromic films in intraoperative radiotherapy of the breast

2020 ◽  
Vol 152 ◽  
pp. S715-S716
Author(s):  
S. Lozares ◽  
A. Gandía ◽  
J.A. Font ◽  
D. Villa ◽  
V. Alba ◽  
...  
Keyword(s):  
Intraoperative Radiotherapy ◽  
In Vivo Dosimetry ◽  
Radiochromic Films

In vivo dosimetry using radiochromic films during intraoperative electron beam radiation therapy in early-stage breast cancer

2003 ◽  
Vol 69 (3) ◽  
pp. 285-289 ◽  
Author(s):  
Mario Ciocca ◽  
Roberto Orecchia ◽  
Cristina Garibaldi ◽  
Elena Rondi ◽  
Alberto Luini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Electron Beam ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
In Vivo Dosimetry ◽  
Beam Radiation ◽  
Radiochromic Films ◽  
Electron Beam Radiation

scholarly journals Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides

Pharmaceutics ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 568 ◽  
Author(s):  
Ulapane ◽  
Kopec ◽  
Siahaan
Keyword(s):  
Monoclonal Antibody ◽  
Blood Brain Barrier ◽  
Cyclic Peptides ◽  
Brain Diseases ◽  
Brain Delivery ◽  
Plasma Stability ◽  
The Novel ◽  
The Brain ◽  
Better Than

Many proteins can be used to treat brain diseases; however, the presence of the blood–brain barrier (BBB) creates an obstacle to delivering them into the brain. Previously, various molecules were delivered through the paracellular pathway of the BBB via its modulation, using ADTC5 and HAV6 peptides. This study goal was to design new cyclic peptides with N-to-C terminal cyclization for better plasma stability and modulation of the BBB. Cyclic HAVN1 and HAVN2 peptides were derived from a linear HAV6 peptide. Linear and N-to-C terminal cyclic ADTHAV peptides were designed by combining the sequences of ADTC5 and HAV6. These novel cyclic peptides were used to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain. Cyclic HAVN1 and HAVN2 peptides deliver IgG into the brain, while the parent linear HAV6 peptide does not. Cyclic and linear ADTHAV and ADTC5 peptides enhanced brain delivery of IgG mAb, in which cyclic ADTHAV peptide was better than linear ADTHAV (p = 0.07). Cyclic ADTHAV and ADTC5 influenced the distribution of IgG mAb in other organs while HAV6, HAVN1 and HAVN2 did not. In summary, the novel cyclic peptides are generally better BBB modulators than their linear counterparts for delivering IgG mAb into the brain.

1095 poster IN VIVO DOSIMETRY WITH RADIOCHROMIC FILMS IN INTRAOPERATIVE RADIATION THERAPY

2011 ◽  
Vol 99 ◽  
pp. S407-S408
Author(s):  
S. Guariglia ◽  
G. Meliadò ◽  
M.G. Giri ◽  
N. Marciai ◽  
C. Cavedon ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Intraoperative Radiation Therapy ◽  
In Vivo Dosimetry ◽  
Intraoperative Radiation ◽  
Radiochromic Films

Applications of Nanoparticles in Herbal Medicine: Zedoary Turmeric Oil and Its Active Compound β-Elemene

2011 ◽  
Vol 39 (06) ◽  
pp. 1093-1102 ◽  
Author(s):  
Meiwan Chen ◽  
Shengpeng Wang ◽  
Miao Tan ◽  
Yitao Wang
Keyword(s):  
Drug Delivery ◽  
Anticancer Agents ◽  
The Novel ◽  
Hydrophobic Properties ◽  
Low Toxicity ◽  
Aqueous Solubilities ◽  
Novel Drug ◽  
The Brain

Zedoary turmeric oil and its main active ingredient β-elemene are novel plant-derived anticancer agents with long-term clinical application history and low toxicity, which have been approved by the Chinese SFDA to treat different tumors including cancers of the brain, ovary, prostate, breast, lungs, liver, colon, and other tissues. Unfortunately, their hydrophobic properties, poor stabilities and low bioavailabilities seriously hamper their applications in clinic. Therefore, more attention should be paid to develop novel drug delivery systems for zedoary turmeric oil and β-elemene to enhance their overall quality. Recently, increased research has been carried out on a nanoparticle drug delivery system of zedoary turmeric oil and β-elemene to solve their poor aqueous solubilities and low bioavailabilities in vivo with much remarkable achievements springing up in the last decade. This review presents the novel nanoparticle formulations of zedoary turmeric oil and β-elemene and introduces the possible future prospects of their further study.

scholarly journals Role of in vivo dosimetry with radiochromic films for dose verification during cutaneous radiation therapy

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Hong-Wei Liu ◽  
James Gräfe ◽  
Rao Khan ◽  
Ivo Olivotto ◽  
J Eduardo Villarreal Barajas
Keyword(s):  
Radiation Therapy ◽  
In Vivo Dosimetry ◽  
Dose Verification ◽  
Radiochromic Films

scholarly journals Tissue-Specific Regulation of HNK-1 Biosynthesis by Bisecting GlcNAc

Molecules ◽  
2021 ◽  
Vol 26 (17) ◽  
pp. 5176
Author(s):  
Haruka Kawade ◽  
Jyoji Morise ◽  
Sushil K. Mishra ◽  
Shuta Tsujioka ◽  
Shogo Oka ◽  
...  
Keyword(s):  
Dynamics Simulation ◽  
The Novel ◽  
Tissue Specific ◽  
Synaptic Functions ◽  
The Difference ◽  
Specific Regulation ◽  
The Brain ◽  
Bisecting Glcnac

Human natural killer—1 (HNK-1) is a sulfated glyco-epitope regulating cell adhesion and synaptic functions. HNK-1 and its non-sulfated forms, which are specifically expressed in the brain and the kidney, respectively, are distinctly biosynthesized by two homologous glycosyltransferases: GlcAT-P in the brain and GlcAT-S in the kidney. However, it is largely unclear how the activity of these isozymes is regulated in vivo. We recently found that bisecting GlcNAc, a branching sugar in N-glycan, suppresses both GlcAT-P activity and HNK-1 expression in the brain. Here, we observed that the expression of non-sulfated HNK-1 in the kidney is unexpectedly unaltered in mutant mice lacking bisecting GlcNAc. This suggests that the biosynthesis of HNK-1 in the brain and the kidney are differentially regulated by bisecting GlcNAc. Mechanistically, in vitro activity assays demonstrated that bisecting GlcNAc inhibits the activity of GlcAT-P but not that of GlcAT-S. Furthermore, molecular dynamics simulation showed that GlcAT-P binds poorly to bisected N-glycan substrates, whereas GlcAT-S binds similarly to bisected and non-bisected N-glycans. These findings revealed the difference of the highly homologous isozymes for HNK-1 synthesis, highlighting the novel mechanism of the tissue-specific regulation of HNK-1 synthesis by bisecting GlcNAc.

Sign in / Sign up

Export Citation Format

Share Document